With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. We invest in all stages of enterprise development and growth - from early stage to late stage. Our unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company